Long lasting drug formulations
First Claim
1. A long-lasting therapeutic formulation comprising a genetically modified micro-organ, said micro organ comprising a vector comprising a nucleic acid sequence operably linked to one or more regulatory sequences, wherein said nucleic acid sequence encodes a therapeutic polypeptide and whereby said formulation increases expression levels of said therapeutic polypeptide by more than 5% over basal levels and said increased levels persist for greater than one month.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to long-lasting therapeutic formulations and their methods of use wherein the formulation comprises a genetically modified micro-organ that comprises a vector which comprises a nucleic acid sequence operably linked to one or more regulatory sequences, wherein the nucleic acid sequence encodes a therapeutic polypeptide, such as erythropoietin or interferon alpha.
-
Citations
107 Claims
- 1. A long-lasting therapeutic formulation comprising a genetically modified micro-organ, said micro organ comprising a vector comprising a nucleic acid sequence operably linked to one or more regulatory sequences, wherein said nucleic acid sequence encodes a therapeutic polypeptide and whereby said formulation increases expression levels of said therapeutic polypeptide by more than 5% over basal levels and said increased levels persist for greater than one month.
-
5. (canceled)
-
9. (canceled)
-
16. A method of providing a therapeutic polypeptide to a subject in need over a sustained period comprising:
-
a. providing a formulation comprising one or more genetically modified micro-organs, said micro-organs comprising a vector comprising a nucleic acid sequence operably linked to one or more regulatory sequences; and
b. implanting said genetically modified micro-organ in said subject, wherein said nucleic acid sequence encodes said therapeutic polypeptide and whereby said therapeutic polypeptide levels are increased by more than 5% over basal levels and said increased therapeutic polypeptide expression levels are maintained for greater than one month. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
-
33-99. -99. (canceled)
- 100. A nucleic acid sequence with greater than 85% homology to SEQ ID No:
- 103. A nucleic acid sequence with greater than 85% homology to SEQ ID No:
Specification